News Releases | LexaGene

LexaGene Adopts Corporate Governance Charters and Policies

September 18, 2021

BEVERLY, Mass. – September 17, 2021 – LexaGene Holdings, Inc. (OTCQB: LXXGF; TSX-V: LXG) ("LexaGene" or "the Company"), a molecular diagnostics company developing automated rapid polymerase…

LexaGene Enters into Cooperative Research and Development Agreement with the United States Army’s Combat Capabilities Development Command

September 16, 2021

BEVERLY, Mass. – September 16, 2021 – LexaGene Holdings, Inc. (OTCQB: LXXGF; TSX-V: LXG) ("LexaGene" or "the Company"), a molecular diagnostics company developing automated rapid polymerase…

LexaGene’s MiQLab™ Accurately Detects Multiple Strains of Pathogenic Bacteria in Polymicrobial Samples Compared to Conventional Culture

September 7, 2021

MiQLab detected both bacterial strains in polymicrobial samples in ~2 hours. Culture and Sensitivity Testing (C&ST) failed to detect the minor pathogen population in individual…

LexaGene Files Preliminary Short Form Base Shelf Prospectus

September 6, 2021

BEVERLY, Mass. – September 3, 2021 – LexaGene Holdings, Inc. ("the Company"), (OTCQB: LXXGF; TSX-V: LXG), a molecular diagnostics company that develops fully automated rapid…

LexaGene’s MiQLab™ System Featured at Three Key Veterinary Tradeshows

September 3, 2021

On-site demonstrations will spotlight how MiQLab’s next-generation technology is advancing veterinary PCR diagnostic testing. September 7-9, WVC 93rd Annual Conference, Las Vegas, NV September 12-14,…

LexaGene Demonstrates Simple, Inexpensive Multiplex PCR Chemistry with Shorter Lead Times for Use on its MiQLab System

August 12, 2021

First point-of-need PCR system capable of using conventional probe-based chemistry or inexpensive, rapidly available SYBR Green chemistry. BEVERLY, Mass. – Aug 12, 2021 – LexaGene Holdings,…

LexaGene’s MiQLab Detects Common Bioreactor Contaminant up to 300 Times Faster than Conventional Methods

July 20, 2021

Mycoplasmas are thought to contaminate 15-80% of cell cultures worldwide. MiQLab rapidly detected 100% of the tested mycoplasma samples within two hours, with no false…

LexaGene Retains Wolf Greenfield Intellectual Property Law Firm

July 14, 2021

Announces participation in national investor conference and webcast on Thursday, July 15 BEVERLY, Mass. USA – July 14, 2021 – LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG)…

LexaGene Launches 2nd Generation Bacterial and Drug Resistance Test to Better Meet the Diagnostic Needs of Veterinarians

July 7, 2021

New panel offers extensive improvements for pathogen identification and drug resistance gene testing Increases targeted pathogens from 7 to 10 (140% of the original) Increases…

LexaGene Advances Towards FDA Emergency Use Authorization

July 2, 2021

BEVERLY, Mass. USA – July 2, 2021 – LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen…